Valevia UK is a privately owned healthcare company headquartered in the UK.
Valevia has an internationally-experienced senior management team with a track record of successful drug development and marketing, as well as business development and licensing.
Valevia is dedicated to the development of innovative therapies for unmet medical needs, including hard-to treat hospital antibacterial infections.
Valevia UK licenses products in early stages of development and develops them in order to outlicense them at a later stage in development. Valevia’s lead project (VAL301) is an anti-Gram(+) agent suitable for use as a topical treatment of SSTIs and/or oral treatment of C. Difficile infection.